Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)

Carcinogenesis

Volumn 20, Issue 9, 1999, Pages 1727-1731

  Lunn, Ruth M ^a   Bell, Douglas A ^a   Mohler, James L ^b   Taylor, Jack A ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID 17ALPHA MONOOXYGENASE; STEROID REDUCTASE;

ALLELE; ARTICLE; CANCER RISK; CAUCASIAN; ENZYME POLYMORPHISM; ETHNIC GROUP; GENE FREQUENCY; GENETIC RISK; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOCARCINOMA; AFRICAN CONTINENTAL ANCESTRY GROUP; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DIHYDROTESTOSTERONE; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ISOENZYMES; MALE; NEOPLASMS, HORMONE-DEPENDENT; NORTH CAROLINA; ODDS RATIO; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK; STEROID 17-ALPHA-HYDROXYLASE; TAIWAN; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0032846313     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/20.9.1727     Document Type: Article

References (36)

1. Landis, S.H., Murray, T., Bolden, S. and Wingo, P.A. (1998) Cancer statistics, 1998. CA Cancer J. Clin., 48, 6-29.
2. Ilic, M., Vlajinac, H. and Marinkovic, J. (1996) Case-control study of risk factors for prostate cancer. Br. J. Cancer, 74, 1682-1686.
3. Daviglus, M.L., Dyer, A.R., Persky, V., Chavez, N., Drum, M., Goldberg, J., Liu, K., Morris, D.K., Shekelle, R.B. and Stamler, J. (1996) Dietary beta-carotene, vitamin C, and risk of prostate cancer: results from the Western Electric Study [see comments]. Epidemiology, 7, 472-477.
4. Lumey, L.H. (1996) Prostate cancer and smoking: a review of case-control and cohort studies [published erratum appears in Prostate (1996) 29, 402]. Prostate, 29, 249-260.
5. van der Gulden, J.W., Kolk, J.J. and Verbeek, A.L. (1992) Prostate cancer and work environment [see comments]. J. Occup. Med., 34, 402-409.
6. Whittemore, A.S. (1994) Trends in prostate cancer incidence and mortality. In Doll, R., Fraumeni, J.F. and Muir, C.S. (eds), Cancer Surveys. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
7. Parkin, D.M., Pisani, P. and Ferlay, J. (1993) Estimates of the worldwide incidence of eighteen major cancers in 1985. Int. J. Cancer, 54, 594-606.
8. Neuhausen, S.L., Skolnick, M.H. and Cannon-Albright, L. (1997) Familial prostate cancer studies in Utah. Br. J. Urol., 79 (Suppl. 1), 15-20.
9. Steinberg, G.D., Carter, B.S., Beaty, T.H., Childs, B. and Walsh, P.C. (1990) Family history and the risk of prostate cancer. Prostate, 17, 337-347.
10. Lee, C. (1997) Cellular interactions in prostate cancer. Br. J. Urol., 79 (Suppl. 1), 21-27.
11. Gann, P.H., Hennekens, C.H., Ma, J., Longcope, C. and Stampfer, M.J. (1996) Prospective study of sex hormone levels and risk of prostate cancer [see comments]. J Natl Cancer Inst., 88, 1118-1126.
12. Carter, H.B., Pearson, J.D., Metter, E.J., Chan, D.W., Andres, R., Fozard, J.L., Rosner, W. and Walsh, P.C. (1995) Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate, 27, 25-31.
13. Nomura, A.M., Stemmermann, G.N., Chyou, P.H., Henderson, B.E. and Stanczyk, F.Z. (1996) Serum androgens and prostate cancer. Cancer Epidemiol. Biomarkers Prev., 5, 621-625.
14. Vatten, L.J., Ursin, G., Ross, R.K., Stanczyk, F.Z., Lobo, R.A., Harvei, S. and Jellum, E. (1997) Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol. Biomarkers Prev., 6, 967-969.
15. Waterman, M.R. and Keeney, D.S. (1992) Genes involved in androgen biosynthesis and the male phenotype. Horm. Res., 38, 217-221.
16. Feigelson, .S., Shames, L.S., Pike, M.C., Coetzee, G.A., Stanczyk, F.Z. and Henderson, B.E. (1998) Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res., 58, 585-587.
17. Stanford, J.L., Just, J.J., Gibbs, M., Wicklund, K.G., Neal, C.L., Blumenstein, B.A. and Ostrander, E.A. (1997) Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res., 57, 1194-1198.
18. Feigelson, H.S., Ross, R.K., Yu, M.C., Coetzee, G.A., Reichardt, J.K. and Henderson, B.E. (1996) Genetic susceptibility to cancer from exogenous and endogenous exposures. J. Cell Biochem., 25 (suppl.), 15-22.
19. Choong, C.S., Kemppainen, J.A., Zhou, Z.X. and Wilson, E.M. (1996) Reduced androgen receptor gene expression with first exon CAG repeat expansion. Mol. Endocrinol., 10, 1527-1535.
20. Ingles, S.A., Ross, R.K., Yu, M.C., Irvine, R.A., La Pera, G., Haile, R.W. and Coetzee, G.A. (1997) Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor [see comments]. J. Natl Cancer Inst., 89, 166-170.
21. Makridakis, N., Ross, R.K., Pike, M.C., Chang, L., Stanczyk, F.Z., Kolonel, L.N., Shi, C.Y., Yu, M.C., Henderson, B.E. and Reichardt, J.K. (1997) A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res., 57, 1020-1022.
22. Reichardt, J.K., Makridakis, N., Henderson, B.E., Yu, M.C., Pike, M.C. and Ross, R.K. (1995) Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res., 55, 3973-3975.
23. Kantoff, P.W., Febbo, P.G., Giovannucci, E., Krithivas, K., Dahl, D.M., Chang, G., Hennekens, C.H., Brown, M. and Stampfer, M.J. (1997) A polymorphism of the 5α-reductase gene and its association with prostate cancer: a case-control analysis. Cancer Epidemiol. Biomarkers Prev., 6, 189-192.
24. Davis, D.L. and Russell, D.W. (1993) Unusual length polymorphism in human steroid 5α-reductase type 2 gene (SRD5A2). Hum. Mol. Genet., 2, 820.
25. Ross, R.K., Bernstein, L., Lobo, R.A., Shimizu, H., Stanczyk, F.Z., Pike, M.C. and Henderson, B.E. (1992) 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet, 339, 887-889.
26. Taylor, J.A., Hirvonen, A., Watson, M., Pittman, G., Mohler, J.L. and Bell, D.A. (1996) Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res., 56, 4108-4110.
27. Bell, D.A., Taylor, J.A., Butler, M.A., Stephens, E.A., Wiest, J., Brubaker, L.H., Kadlubar, F.F. and Lucier, G.W. (1993) Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis, 14, 1689-1692.
28. Bell, D.A., Taylor, J.A., Paulson, D.F., Robenson, C.N., Mohler, J.L. and Lucier, G.W. (1993) Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J. Natl Cancer Inst., 85, 1159-1164.
29. Stephens, E.A., Taylor, J.A., Kaplan, N., Yang, C.H., Hsieh, L.L, Lucier, G.W. and Bell, D.A. (1994) Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics, 4, 185-192.
30. Watson, M.A., Stewart, R.K., Smith, G.B., Massey, T.E. and Bell, D.A. (1998) Human glutathione 5-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis, 19, 275-280.
31. Hsieh, L.L. and Hsieh, T.T. (1993) Detection of aflatoxin B1-DNA adducts in human placenta and cord blood. Cancer Res., 53, 1278-1280.
32. Wu, A.H., Whittemore, A.S., Kolonel, L.N., John, E.M., Gallagher, R.P., West, D.W., Hankin, J., Teh, C.Z., Dreon, D.M. and Paffenbarger, R.S Jr (1995) Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol. Biomarkers Prev., 4, 735-741.
33. Gharani, N., Waterworth, D.M., Williamson, R. and Franks, S. (1996) 5′ polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries [letter]. J. Clin. Endocrinol Metab., 81, 4174.
34. Helzlsouer, K.J., Huang, H.Y., Strickland, P.T., Hoffman, S., Alberg, A.J., Comstock, G.W. and Bell, D.A. (1998) Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol. Biomarkers Prev., 7, 945-949.
35. Weston, A., Pan, C.F., Bleiweiss, I.J., Ksieski, H.B., Roy, N., Maloney, N. and Wolff, M.S. (1998) CYP17 genotype and breast cancer risk [In Process Citation]. Cancer Epidemiol. Biomarkers Prev., 7, 941-944.
36. Galbraith, S.M. and Duchesne, G.M. (1997) Androgens and prostate cancer: biology, pathology and hormonal therapy. Eur. J. Cancer, 33, 545-554.